Verona Pharma plc — Director's Dealing 2024

Apr 30, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2024-04-29

Reporting Person: SHAH MAHENDRA (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-04-29	Share Options (Right to Buy)	$1.9338	A	240000	Acquired	2034-04-28	Ordinary Shares (240000)	Direct

Footnotes

F1: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer.

F2: The option vests and becomes exercisable as to 25% on each of July 29, 2024, October 29, 2024, January 29, 2025 and April 29, 2025.